We’re excited to share Dr. Kevin Magnaye, Caris Life Sciences #data scientist and a Clinical Research Achievement Award recipient, recently discussed his #research and career insights with the Journal of Clinical and Translational Science. Read more: ow.ly/7QeZ50R6O0B

Thanks to Dr. Bui Pathologist🌼 for the opportunity to talk about our pathologists excellent work Caris Life Sciences and how we distribute it among our group.

Had a blast attending my first #AACR2024 annual meeting and presenting our work on the #TEM8 receptor, an attractive target in Neuroendocrine Neoplasms (NENs, including #NETs )

Stay tuned for Phase 1 trial! 💊

Media: news.med.miami.edu/combining-immu…

Review: pubmed.ncbi.nlm.nih.gov/37998358/

Treatment options for patients with rare, aggressive cancers that have no targeted therapies or clinical trials can be challenging. Hear Dr. Pooja Advani from Mayo Clinic discuss the molecular and immune landscape of Triple-Negative Invasive Lobular Carcinoma (TN-ILC) at #AACR24 .

Can targeting PIM kinases enhance the activity of immunotherapy in prostate cancer? Hear Amber Clements from University of Arizona Cancer Center discuss molecular and immune profiling in primary and metastatic tumors, as well as research in primary cells and mouse models that say yes. #AACR24

Does high expression of the TEM8 receptor make neuroendocrine neoplasms (NENs) more amenable to immunotherapy? Hear Dr. Samuel Kareff, MD, MPH from Sylvester Comprehensive Cancer Center discuss molecular and immune profiles of over 1,700 NENs clustered by TEM8/ANTRX1 expression level. #AACR24

There's still time to connect with Caris during #AACR24 . Visit our team at booth 1105. AACR
carislifesciences.com

Today, Caris Life Sciences President Dr. David Spetzler presented during an #AACR24 session, “Very Early Cancer Detection Assays: The Future or Fantasy,” for the Scientist↔Survivor Program.

The program is designed for partnerships among the scientific, cancer survivor, and

Exploring #AACR24 ? Stop and chat with Caris experts at booth 1105 for info on the latest precision oncology advancements. ow.ly/nNjR50Rbvn6

What role does the PDLIM2 tumor suppressor gene play in lung adenocarcinoma and squamous non-small cell lung cancer NSCLC? Join Dr. Karam Ashouri from Keck School of Medicine of USC as he explores WES and WTS of 29k+ NSCLC cases from the Caris clinicogenomic database. #AACR24 AACR

Caris and collaborators within the Caris Precision Oncology Alliance (POA) are currently presenting a variety of studies during #AACR24 . Explore these posters and discover the value of Caris’ comprehensive molecular profiling and large-scale collaboration between the growing…

Caris Biopharma Solutions is at the intersection of molecular and real-world data. The breadth and depth of our multi-modal data offerings help you make smarter therapeutic development decisions with greater efficiency and reduced risk. Learn how during #AACR24 at booth 1105.

Great to visit poster by colleagues on
AI-enabled whole exome/transcriptome liquid biopsy in oncology

I had an opportunity to speak with the presenters about the findings at the AACR meeting #AACR24 in San Diego Caris Life Sciences

#AACR24 Poster Presentation - Maria Perdigones and Sergey Klimov presented 'AI-enabled whole exome & transcriptome liquid biopsy addressing MCED, MRD, and therapy selection on a single platform.'
Learn more: ow.ly/hjz850RaUCu

What are the molecular underpinnings of cervical cancer metastasis to different sites? Hear Dr. Matthew Hadfield from Legorreta Cancer Center at Brown University discuss detailed molecular and immune portraits of over 2,600 cervical cancer samples. #AACR24
ow.ly/njiq50RaHAL

Can novel therapeutic targets in lung adenocarcinomas be identified with different driver mutations? Dr. Andrew Swartz discusses an analysis of surfaceome and cancer testis (CT) antigen candidate genes by WES and WTS of 9,000 tumors. #AACR24
ow.ly/PEOE50RaH3w

Caris Life Sciences President, Dr. David Spetzler, will present a special interest session titled 'Very Early Cancer Detection Assays: The Future or Fantasy' for the AACR Scientist↔Survivor Program. #AACR24

Our team is waiting to chat with you at booth 1105. Take advantage of the opportunity to network with Caris during #AACR24 . carislifesciences.com

Caris Assure couples WES/WTS on white blood cells and plasma with machine learning to provide early cancer diagnosis, minimal residual disease (MRD), and therapy selection on one platform. Catch the presentation during #AACR24 . ow.ly/5Vax50Rav05